Figure 4.

TRA-8 treatment reduced tissue inflammation and autoantibodies, and increased the lifespan of death receptor 5 (DR5)-transgenic B6-me^v/me^v mice. A, Kaplan–Meyer survival curve of TRA-8– and isotype control– treated DR5-transgenic B6-me^v/me^v mice (~15 mice/group). B, Left panels, Effect of TRA-8 treatment on the lung and joints of DR5-transgenic B6-me^v/me^v mice. Right panels, Quantification of bone erosion, synovitis and Mac-3–positive cells in the lungs and joints of mice treated with TRA-8 or isotype control. C, Serum levels of anti-histone and anti–double-stranded DNA (anti-dsDNA) antibodies in DR5-transgenic B6-me^v/me^v mice treated with TRA-8 or isotype control. D, Left panels, Effect of TRA-8 treatment on the kidneys of DR5-transgenic B6-me^v/me^v mice compared with the isotype control treatment. Right panels, Quantification of renal pathology scores and IgG and IgM deposits in the glomeruli of mice treated with TRA-8 or isotype control. Values are the mean (± SEM) (n = 5 mice per group except panel A). * = P < 0.05, ** = P < 0.01, *** = P <.001. Bars = 100μm. H&E = hematoxylin and eosin, hpf = high-power field.